





# Radiation Quality in Ion Beam Therapy: How to take into account the RBE?

M. Scholz  
GSI Darmstadt

# Advantage of ion beams: physical



# Increased Relative Biological Effectiveness: RBE



Weyrather et al.

Differential Effect:


Enhancement(Peak)

>>

Enhancement(Plateau)

( Neutrons:  
Enhancement  
everywhere!!! )

# Definition: Relative Biological Effectiveness (RBE)



$$S = e^{-(\alpha D + \beta D^2)}$$

$$\alpha_{Ion} \geq \alpha_{Photon}$$

$$\beta_{Ion} \leq \beta_{Photon}$$

$$RBE = \frac{D_{Photon}}{D_{Ion}} \Big|_{Isoeffect}$$

$$RBE_{\alpha} = \frac{\alpha_{Ion}}{\alpha_{Photon}}$$

# Requirements for Treatment Planning

Challenge:

Homogenous distribution of effective dose in treatment volume


Effective dose distribution in normal tissues

$$D_{RBE} = D_{Phys} \cdot RBE(Z, E, D, \alpha, \beta, p_{O_2}, \dots)$$



RBE depends on several factors:

- Particle species / LET
- Dose
- Cell / Tissue type
- Oxygen status
- ...


# LET $\leftrightarrow$ Depth Dependence of RBE



Weyrather et al. IJRB 1999




# Dependence of RBE on ion species



➔ RBE higher for light as compared to heavier ions at given LET



# Depth Dependence of RBE





Reduction of dose towards distal peak  
to account for increase of RBE



# Dose Dependence of RBE



*In-vitro:*  
Cell survival / CHO-cells




Weyrather et al., IJRB 1999

**➔** RBE decreases with Dose

# Dependence of RBE on Effect Level




Endpoint: HSG cell survival in-vitro



Shape depends on effect level


Relevant for hypofractionation

# Cell type dependence of RBE I




Increase of RBE more pronounced for resistant cells  
as compared to sensitive cells

# Cell type dependence of RBE II



Weyrather et al. IJRB 1999


## Photons




RBE is correlated with repair capacity  
(In terms of LQ-model: with  $(\alpha/\beta)_{\text{Photon}}$ -ratio)

# Treatment planning for carbon ions

Complex RBE dependencies: E, LET, D, cell type,...



Interpolation/extrapolation required for  
treatment planning in HI therapy



## HIMAC

Experimental Data  
+ Clinical Neutron Experience  
(,Fixed' RBE-scheme)

## GSI / HIT

Biophysical Modelling  
(Local Effect Model LEM)  
(Variable RBE-scheme)

# HIMAC - Approach

**In-vitro Experiments**  
(Monoenergetic, high-LET)  
 $\alpha_{\text{Carbon}}(x), \beta_{\text{Carbon}}(x)$




**Algorithm:**  
Dose Weighted Average  
 $\alpha_{\text{Mix}} = \sum f_i \alpha_i \quad \sqrt{\beta_{\text{Mix}}} = \sum f_i \sqrt{\beta_i}$




**Relative Shape of**  
Depth Dose Distribution





**Absolute RBE:**  
Clinical Neutron Experience



Treatment Planning



# GSI Approach: Basics of Modelling






# GSI Approach: Local Effect Model LEM


## Basic Assumption:

Increased effectiveness of particle radiation can be described by a combination of the **photon dose response** and **microscopic dose distribution**

**Local Effect (Photons) = Local Effect (Ions)**




+



➔ **RBE !**

LEM: Transfer of low-LET experience to high-LET


# Comparison LEM IV – Experimental Data



# Carbon ions vs. protons

First radiobiology experiments at **HIT** facility:



➔ **Direct comparison of protons and carbon ions**



Experimental data: Weyrather et al.

Model: LEM IV (Elsässer et al, IJROBP 2010)

# Cell type dependence: transfer to *in-vivo*



Experimental Data: Suzuki et al., *IJROBP* 2000  
 LEM III: Elsässer et al., *IJROBP* 2008


RBE increases with increasing  $(\beta/\alpha)_\gamma$ -ratio

Assumption for application *in-vivo*:

$$\text{RBE}(\beta/\alpha)_{in-vitro} = \text{RBE}(\beta/\alpha)_{in-vivo}$$

# Comparison LEM – Experimental Data

## *In-vivo*: Tolerance of Rat Spinal Cord




Exp. Data: Karger et al. *IJROBP* 2006


LEM IV: Elsässer et al., *IJROBP* 2010

# Influence of Tissue Composition


Tumor  
Normal 1  
Normal 2  
Normal 3



Tissue dependence  
of RBE might lead to  
discontinuities of the  
RBE-weighted dose  
distribution!




# Comparison with clinical data: tumor control



R. Grün et al., PMB 2012



# Comparison LEM – HIMAC approach



Comparison  
LEM I / LEM IV

Conversion  
HIMAC based  
RBE-weighted dose  
vs.  
LEM based  
RBE-weighted dose

O. Steinsträter et al., IJROBP 2012

# Summary

- RBE depends on position in SOBP, dose level and biological system
- Interpolation / extrapolation of experimental data and/or modelling are required to represent these dependencies in treatment planning
- LEM has been implemented in the TRiP treatment planning environment for the GSI pilot project and in the Siemens TPS
- Consideration of dose dependent and tissue specific RBE values is crucial e.g. for hypofractionation studies
- Differences between HIMAC and GSI/HIT approach need to be taken into account when interpreting RBE-weighted dose values